New drug aims to prevent bleeding in hemophilia patients
NCT ID NCT07545395
First seen May 02, 2026 · Last updated May 17, 2026 · Updated 4 times
Summary
This study tests a new medicine called KN057 given regularly to prevent bleeding episodes in people with hemophilia A or B, including those whose bodies have developed resistance to standard treatments. About 70 males aged 12 to 65 will receive weekly injections for up to 52 weeks. The main goal is to check safety and how well the drug works over the long term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A OR B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact
Conditions
Explore the condition pages connected to this study.